Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793625 | 0.78 | CHRNB4 (0.37) | PARP3CHRNB4CHRNA3PAX8KCNH2 | |
| SCHEMBL29636531 | 0.78 | CHRNB4 (0.37) | PARP3CHRNB4CHRNA3PAX8KCNH2 | |
| SCHEMBL8703745 | 0.78 | CHRNB4 (0.37) | PARP3CHRNB4CHRNA3PAX8KCNH2 | |
| SCHEMBL17749125 | 0.74 | PAX8 (0.32) | PARP3PAX8GBA1 | |
| SCHEMBL19277393 | 0.74 | PAX8 (0.32) | PARP3PAX8GBA1 | |
| SCHEMBL30417082 | 0.73 | CHRNB4 (0.39) | PARP3CHRNB4CHRNA3PAX8MEN1 | |
| SCHEMBL4198061 | 0.72 | HTR1A (0.37) | PARP3PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL4198060 | 0.72 | HTR1A (0.37) | PARP3PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL4198062 | 0.72 | HTR1A (0.37) | PARP3PAX8MEN1KMT2AALDH1A1 | |
| SCHEMBL5507570 | 0.72 | HTR1A (0.37) | PARP3PAX8MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0142241-B1 | DIHYDROXYBENZAMIDE DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-12-02 | — | — | EP | claimed |
| EP-0142241-A1 | Dihydroxybenzamide derivatives having anti-inflammatory activity | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-05-22 | — | — | EP | claimed |
| WO-2009103007-A2 | STEROID HORMONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | PARP3 2654/4885CHRNB4 378/4885CHRNA3 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.